Literature DB >> 8042914

Neuropsychological functioning in siblings discordant for schizophrenia and healthy volunteers.

T D Cannon1, L E Zorrilla, D Shtasel, R E Gur, R C Gur, E J Marco, P Moberg, R A Price.   

Abstract

OBJECTIVE: To determine whether schizophrenics and their nonschizophrenic siblings have a similar pattern of neuropsychological deficit when compared with normal controls. DESIGN AND PARTICIPANTS: Fifteen probands with schizophrenia, 16 of their nonschizophrenic siblings, and 31 unrelated, demographically balanced, normal individuals underwent evaluation with a comprehensive neuropsychological test battery. All subjects were screened for history of head injury, neurologic illness, major medical conditions, substance use, and axis I psychiatric disorders other than schizophrenia. Probands underwent evaluation twice: once at intake when half had never received neuroleptic medication and the other half had received none for a minimum of 2 weeks, and again at the 2- to 4-week follow-up, after stabilization with neuroleptic medications.
RESULTS: Both schizophrenics and their nonschizophrenic siblings were impaired neuropsychologically compared with normal controls, with the nonschizophrenic siblings' performance intermediate between that of the schizophrenic siblings and the normal controls on all measures of functioning. The shapes of the deficit profiles of schizophrenic patients and their siblings were similar; in patients, verbal memory, abstraction, attention, and language functions were significantly more affected compared with spatial abilities, spatial memory, and sensory-motor functions, with a nonsignificant trend in the same direction in siblings. Cognitive functioning in patients was found to be stable across changes in medication status and clinical state. Four fifths of patients obtained more deviant scores than their nonschizophrenic siblings. Among the sibling group, those with probable and certain diagnoses of schizotypal personality disorder were more impaired compared with those without schizophrenia-spectrum symptoms.
CONCLUSION: These results support the hypothesis that impaired information processing aggregates in the family members of schizophrenics and may serve as an indicator of genetic vulnerability to the disorder. Further work is needed to establish whether particular areas of functioning are selectively impaired in relatives and to determine whether the performance deficits are mediated by structural and/or metabolic disturbances in specific brain regions.

Entities:  

Mesh:

Year:  1994        PMID: 8042914     DOI: 10.1001/archpsyc.1994.03950080063009

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  44 in total

Review 1.  The genetics of sensory gating deficits in schizophrenia.

Authors:  Robert Freedman; Ann Olincy; Randall G Ross; Merilyne C Waldo; Karen E Stevens; Lawrence E Adler; Sherry Leonard
Journal:  Curr Psychiatry Rep       Date:  2003-06       Impact factor: 5.285

Review 2.  Genetic architecture of declarative memory: implications for complex illnesses.

Authors:  Carrie E Bearden; Katherine H Karlsgodt; Peter Bachman; Theo G M van Erp; Anderson M Winkler; David C Glahn
Journal:  Neuroscientist       Date:  2011-08-10       Impact factor: 7.519

3.  A closer look at siblings of patients with schizophrenia: the association of depression history and sex with cognitive phenotypes.

Authors:  Krista M Wisner; Brita Elvevåg; James M Gold; Daniel R Weinberger; Dwight Dickinson
Journal:  Schizophr Res       Date:  2010-10-28       Impact factor: 4.939

Review 4.  Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes.

Authors:  Beth E Snitz; Angus W Macdonald; Cameron S Carter
Journal:  Schizophr Bull       Date:  2005-09-15       Impact factor: 9.306

Review 5.  Hippocampal function, declarative memory, and schizophrenia: anatomic and functional neuroimaging considerations.

Authors:  Alison R Preston; Daphna Shohamy; Carol A Tamminga; Anthony D Wagner
Journal:  Curr Neurol Neurosci Rep       Date:  2005-07       Impact factor: 5.081

6.  Biological phenotypes and genetic research on schizophrenia.

Authors:  Daniel R Weinberger
Journal:  World Psychiatry       Date:  2002-02       Impact factor: 49.548

7.  Neuropsychological functioning of siblings of children with autism, siblings of children with developmental language delay, and siblings of children with mental retardation of unknown genetic etiology.

Authors:  Tammy Pilowsky; Nurit Yirmiya; Varda Gross-Tsur; Ruth S Shalev
Journal:  J Autism Dev Disord       Date:  2007-03

8.  Group and site differences on the California Verbal Learning Test in persons with schizophrenia and their first-degree relatives: findings from the Consortium on the Genetics of Schizophrenia (COGS).

Authors:  William S Stone; Anthony J Giuliano; Ming T Tsuang; David L Braff; Kristin S Cadenhead; Monica E Calkins; Dorcas J Dobie; Stephen V Faraone; Robert Freedman; Michael F Green; Tiffany A Greenwood; Raquel E Gur; Ruben C Gur; Gregory A Light; Jim Mintz; Keith H Nuechterlein; Ann Olincy; Allen D Radant; Andrea H Roe; Nicholas J Schork; Larry J Siever; Jeremy M Silverman; Neal R Swerdlow; Alison R Thomas; Debby W Tsuang; Bruce I Turetsky; Larry J Seidman
Journal:  Schizophr Res       Date:  2011-02-01       Impact factor: 4.939

Review 9.  Biomarkers in psychosis: an approach to early identification and individualized treatment.

Authors:  Heline Mirzakhanian; Fiza Singh; Kristin S Cadenhead
Journal:  Biomark Med       Date:  2014       Impact factor: 2.851

10.  Decreased white matter FA values in the left inferior frontal gyrus is a possible intermediate phenotype of schizophrenia: evidences from a novel group strategy.

Authors:  Jianjun Ou; Hailong Lyu; Maorong Hu; Jun Li; Wenbin Guo; Xiaofeng Guo; Lihua Li; Junjie Zheng; Qinling Wei; Feng Liu; Zhong He; Juan Wang; Fang Liu; Renrong Wu; Jindong Chen; Lehua Li; Bin Hu; Huafu Chen; Jingping Zhao
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-12-09       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.